N
News Analysis
investegate.co.uk

www.investegate.co.uk · · GB

Neutral

Prtc S Sptx New Positive Glyphago Ph1 Dosing Data

UpdatessympathyMajor Depressive DisorderScienceMilitary Title Officer

Topic context

This topic has been covered 337071 times in the last 7 days across our monitored publishers.

Related topics

SavunmaSpor

All NewsRead the full story on investegate.co.uk

The full article is on the original publisher site.

Related stories

investegate.co.uk

Results for the Year Ended 31 December 2025

finanzen.ch

abc meta launch $115 mln program to train data center construction workers

digitaljournal.com

Asian Stocks Track Wall Street Tech Bounce Oil Eases on Mideast Hope

econotimes.com

Asian Stocks Rebound as AI and Chip Shares Recover Easing Iran Tensions Boost Sentiment

juancole.com

Iran Axis Empire

News Analysis — AI Analysis

Original analysis generated by News Analysis. This is our own commentary on the story, not the publisher's article text.

Seaport Therapeutics announced positive results from a Phase 1 clinical trial evaluating repeat dosing of its drug candidate, GlyphAgo™, in healthy volunteers. The multiple-ascending dose (MAD) data confirmed that repeated dosing maintained a favorable safety and pharmacokinetic profile compared to previous single-dose studies. These findings support the company's plan to advance GlyphAgo into two parallel Phase 2 trials for treating generalized anxiety disorder (GAD).

Key points

  • GlyphAgo™, an oral prodrug of agomelatine, was tested in a repeat dosing study (MAD portion) during a Phase 1 trial.
  • The MAD data showed that seven-day dosing achieved therapeutic levels of agomelatine while reducing the risk and need for liver function testing.
  • Positive safety and pharmacokinetic profiles support advancing GlyphAgo into two parallel Phase 2 trials for GAD.
  • Phase 2a is planned for the second half of 2026, focusing on objective measures of sleep architecture in GAD patients.
  • Phase 2b, a potentially registration-enabling trial, is expected to begin in the first half of 2027.

Claims assessed

  • VerifiableRepeat dosing of GlyphAgo demonstrated safety and tolerability consistent with previous single-dose studies.
  • VerifiableThe drug candidate, GlyphAgo™, achieved therapeutic exposures of agomelatine at doses that reduce liver enzyme elevations.
  • VerifiableSeaport plans to initiate a Phase 2a trial in the second half of 2026 and expect top-line data in early 2028.

Missing context

The article does not provide the specific primary endpoints or statistical significance data from the Phase 1 MAD portion of the trial, nor does it detail the current competitive landscape for treating generalized anxiety disorder (GAD).

About the publisher

investegate.co.uk is one of the GB en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

investegate.co.uk files this story under "updatessympathy" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.